These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 11816865

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Beneficial effect of donepezil in the treatment of elderly patients with tardive movement disorders.
    Bergman J, Dwolatzky T, Brettholz I, Lerner V.
    J Clin Psychiatry; 2005 Jan; 66(1):107-10. PubMed ID: 15669896
    [Abstract] [Full Text] [Related]

  • 3. Treatment of tardive dyskinesia with donepezil.
    Caroff SN, Campbell EC, Havey JC, Sullivan KA, Katz IR, Mann SC.
    J Clin Psychiatry; 2001 Feb; 62(2):128-9. PubMed ID: 11247101
    [No Abstract] [Full Text] [Related]

  • 4. Buspirone in the treatment of tardive dyskinesia.
    Moss LE, Neppe VM, Drevets WC.
    J Clin Psychopharmacol; 1993 Jun; 13(3):204-9. PubMed ID: 8102622
    [Abstract] [Full Text] [Related]

  • 5. Use of aripiprazole in tardive dyskinesia: an open label study of six cases.
    Rajarethinam R, Dziuba J, Manji S, Pizzuti A, Lachover L, Keshavan M.
    World J Biol Psychiatry; 2009 Jun; 10(4 Pt 2):416-9. PubMed ID: 19492247
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial.
    Keefe RS, Malhotra AK, Meltzer HY, Kane JM, Buchanan RW, Murthy A, Sovel M, Li C, Goldman R.
    Neuropsychopharmacology; 2008 May; 33(6):1217-28. PubMed ID: 17625502
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
    Bai YM, Yu SC, Lin CC.
    J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
    Correll CU, Josiassen RC, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):53-60. PubMed ID: 28839340
    [Abstract] [Full Text] [Related]

  • 13. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods.
    Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H.
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Sep 01; 28(6):985-96. PubMed ID: 15380859
    [Abstract] [Full Text] [Related]

  • 14. Double-blind donepezil-placebo crossover augmentation study of atypical antipsychotics in chronic, stable schizophrenia: a pilot study.
    Risch SC, Horner MD, McGurk SR, Palecko S, Markowitz JS, Nahas Z, DeVane CL.
    Schizophr Res; 2007 Jul 01; 93(1-3):131-5. PubMed ID: 17391930
    [Abstract] [Full Text] [Related]

  • 15. Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: an open-label trial.
    Chung YC, Lee CR, Park TW, Yang KH, Kim KW.
    World J Biol Psychiatry; 2009 Jul 01; 10(2):156-62. PubMed ID: 19514097
    [Abstract] [Full Text] [Related]

  • 16. Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
    Josiassen RC, Kane JM, Liang GS, Burke J, O'Brien CF.
    Psychopharmacol Bull; 2017 Aug 01; 47(3):61-68. PubMed ID: 28839341
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Beneficial effect of donepezil augmentation for the management of comorbid schizophrenia and dementia.
    Stryjer R, Strous RD, Bar F, Werber E, Shaked G, Buhiri Y, Kotler M, Weizman A, Rabey JM.
    Clin Neuropharmacol; 2003 Aug 01; 26(1):12-7. PubMed ID: 12567159
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.